Literature DB >> 7105791

Parkinsonism in the elderly.

M Hildick-Smith.   

Abstract

Considerable advances have been made in the treatment of parkinsonism in the last 10 to 20 years and have brought great benefit to patients of all ages, including the elderly. Whilst levodopa-containing drugs are the mainstay of treatment in the early disabling stages of the disease, providing increased mobility and independence, longer life expectancy and a shorter period of terminal immobility, as patients live longer more advanced manifestations of the condition develop which are more difficult to treat. Diagnostic difficulties in the elderly are discussed and the main conditions affecting treatment and treatment of the different stages of the disease are reviewed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105791

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  2 in total

1.  Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.

Authors:  S G Bowes; P K Clark; A L Leeman; C J O'Neill; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.

Authors:  Kiyoshi Ando; Shigeru Obayashi; Yuji Nagai; Arata Oh-Nishi; Takafumi Minamimoto; Makoto Higuchi; Takashi Inoue; Toshio Itoh; Tetsuya Suhara
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.